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The role of the nucleocapsid protein of HIV-1 Gag in virus assembly was investigated using Gag truncation mutants, a
nucleocapsid deletion mutant, and point mutations in the nucleocapsid region of Gag, in transfected COS cells, and in stable
T-cell lines. Consistent with previous investigations, a truncation containing only the matrix and capsid regions of Gag was
unable to assemble efficiently into particles; also, the pelletable material released was lighter than the density of wild-type
HIV-1. A deletion mutant lacking p7 nucleocapsid but containing the C-terminal p6 protein was also inefficient in particle
release and released lighter particles, while a truncation containing only the first zinc finger of p7 could assemble more
efficiently into virions. These results clearly show that p7 is indispensable for virus assembly and release. Some point
mutations in the N-terminal basic domain and in the basic linker region between the two zinc fingers, which had been
previously shown to have reduced RNA binding in vitro [Schmalzbauer, E., Strack, B., Dannull, J., Guehmann, S., and Moelling,
K. (1996). J. Virol. 70: 771–777], were shown to reduce virus assembly dramatically when expressed in full-length viral clones.
A fusion protein consisting of matrix and capsid fused to a heterologous viral protein known to have nonspecific RNA binding
activity [Ribas, J. C., Fujimura, T., and Wickner, R. B. (1994) J. Biol. Chem. 269: 28420–28428] released pelletable material
slightly more efficiently than matrix and capsid alone, and these particles had density higher than matrix and capsid alone.
These results demonstrate the essential role of HIV-1 nucleocapsid in the virus assembly process and show that the
positively charged N terminus of p7 is critical for this role. © 1998 Academic Press
INTRODUCTION
In retroviruses the process of viral assembly is poorly
understood. Numerous mutational studies and assays
using diverse cell types and expressing systems have
clearly shown that the Gag polyprotein alone is sufficient
to assemble viral particles (reviewed by Wills and Cra-
ven, 1991; Hunter, 1994) but the mechanism and pathway
of viral assembly have not been elucidated. Mutational
analysis suggests that membrane targeting of Gag plays
a critical role (Bryant and Ratner, 1990; Gottlinger et al.,
1989; Yuan et al., 1993; Spearman et al., 1994; Zhou et al.,
1994; Hill et al., 1996) and that certain Gag–Gag interac-
tions may be essential. Different essential assembly do-
mains of Gag polyproteins have been described (Ghey-
sen et al., 1989; Hansen et al., 1990; Rhee and Hunter,
1990; Weldon et al., 1990; Gottlinger et al., 1991;
Hoshikawa et al., 1991; Mergener et al., 1992; Bennett et
al., 1993; Facke et al., 1993; Hong and Boulanger, 1993;
von Poblotzki et al., 1993; Wang and Barklis, 1993; Yuan
et al., 1993; Chazal et al., 1994; Dorfman et al., 1994;
Mammano et al., 1994; Spearman et al., 1994; Wills et al.,
1994; Parent et al., 1995; Srinivasakumar et al., 1995),
however, with the exception of membrane targeting, the
specific functions in viral assembly which are accom-
plished by most of these domains are not fully defined
(Wills and Craven, 1991; Hunter, 1994).
Mutational analysis of Gag in several different retrovi-
ruses demonstrates that the nucleocapsid domain, or in
the case of HIV-1, the C-terminal domain which includes
p7 and p6, is essential for efficient viral assembly (Royer
et al., 1990, 1991; Weldon et al., 1990; Jowett et al., 1992;
Bennett et al., 1993; Hockley et al., 1994; Huang et al.,
1995; Platt and Haffar, 1994; Yu et al., 1995). A recent
study of the effect of nucleocapsid mutations on viral
assembly and RNA encapsidation (Zhang and Barklis,
1997) showed that deletion mutants of nucleocapsid had
reduced assembly efficiency and reduced levels of HIV
RNA in viral particles. Studies of point mutations in nu-
cleocapsids from several viruses have shown that the
conserved cysteine and histidine residues are neces-
sary for encapsidation of viral RNA (Meric and Spahr,
1986; Gorelick et al., 1988, 1990; Meric et al., 1988; Meric
and Goff, 1989; Aldovini and Young, 1990; Clavel and
Orenstein, 1990; Dupraz et al., 1990; Oertle and Spahr,
1990; Aronoff et al., 1993; Dorfman et al., 1993; Sakalian
et al., 1994); most RNA packaging mutants are assembly-
competent, but some point mutations reduce viral as-
sembly approximately 10-fold (Dorfman et al., 1993).
These studies have shown that, in general, packaging of
the viral genome is not required for efficient assembly
and release of particles. In some studies, nucleocapsid
domains can be switched between two retroviruses, and
the resulting chimeric viruses can assemble efficiently
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and capture the RNA appropriate to the nucleocapsid
domain they contain (Dupraz and Spahr, 1992; Berkowitz
et al., 1995; Zhang and Barklis, 1995). However, a recent
study of chimeric viruses consisting of HIV-1 containing
either the entire MMTV NC or the MMTV zinc fingers
substituted for HIV-1 zinc fingers revealed that the NC
domain alone was not sufficient to confer a preference
for packaging MMTV RNA relative to HIV-1 RNA (Poon et
al., 1998). In the reciprocal experiment, HIV-1 NC in an
MMTV/HIV-1 chimera likewise did not enable MMTV to
preferentially package HIV-1 RNA. Apparently in these
chimeras more protein sequences besides NC are re-
quired to confer specificity in packaging.
Deletion or certain point mutations of nucleocapsid in
some viruses (Weldon et al., 1990; Dupraz and Spahr,
1992; Bennett et al., 1993) efficiently abrogates viral as-
sembly. The role of nucleocapsid in assembly could
involve its participation in overall structure or conforma-
tion of the Gag polyprotein, its role in RNA binding, a role
in protein-protein interactions, or an intracellular target-
ing function. Obviously these possibilities are not mutu-
ally exclusive. A recent study (Zhang et al., 1998) con-
cluded that protein–protein interactions were the main
role of nucleocapsid in the assembly process.
Studies of in vitro assembly using purified RSV or HIV
Gag proteins and RNA have demonstrated that the pres-
ence of RNA (but not necessarily viral genomic RNA) was
necessary to stimulate efficient assembly of regular
structures, which included tubular structures of varying
lengths proportional to the length of the added RNA, and
small spherical particles (Campbell and Vogt, 1995, 1997)
These data, taken together with the studies of packaging
mutants of HIV-1 and other retroviruses, point toward the
role of nonspecific, rather than genome-specific, RNA
binding as an important feature of viral assembly.
The structure of the nucleocapsid protein of HIV-1, p7,
has been solved by NMR spectroscopy (Summers et al.,
1992). Extensive biochemical characterization has been
carried out on this protein to elucidate its roles in pack-
aging of the viral genome, enhancement of strand trans-
fer during reverse transcription, and RNA annealing
properties (Green and Berg 1989, 1990; South et al., 1990;
De Rocquigny et al., 1992, 1993; Berkowitz et al., 1993;
Surovoy et al., 1993; Dannull et al., 1994; Muller et al.,
1994; Rodriguez-Rodriguez et al., 1995; Mely et al., 1996;
Schmalzbauer et al., 1996). RNA annealing activity in vitro
depends on the presence of basic regions flanking the
zinc fingers; the fingers themselves are dispensable (De
Rocquigny et al., 1992). The structure of nucleocapsid
bound to a 20-nucleotide oligo containing one of the
stem loops of the HIV-1 packaging sequence has been
reported (De Guzman et al., 1998). This structure reveals
that the zinc fingers participate in specific recognition of
the RNA loop, and the N-terminal basic residues form
electrostatic contacts with the phosphodiester groups of
the RNA stem. The N-terminal basic residues at posi-
tions 3, 7, 10, and 11 are thus involved in non-sequence-
specific RNA binding. A recent study which involved
alanine substitution for basic residues in the N terminus
and central basic domain between the zinc fingers
showed that these residues are also critical for RNA
packaging in transfected cells, but viral assembly was
not significantly affected (Poon et al., 1996). Mutations of
three basic residues (32-RKK-34) in the central domain to
neutral (serine) residues in an infectious viral clone sim-
ilarly failed to show a defect in viral assembly (Ottman et
al., 1995) but did show a significant reduction in viral titer.
An in vitro study of p15, containing both p7 and p6,
demonstrated that RNA annealing by this protein caused
enhanced cleavage by the viral protease (Sheng et al.,
1997; Sheng and Erickson-Viitanen, 1994). Mutation of
the RKK motif to glutamic acid residues eliminated the
RNA enhancement of cleavage, although significant
cleavage was still observed. Mutation of the N-terminal
and central basic residues to asparagines and glu-
tamines reduced RNA annealing activity in vitro (Schmalz-
bauer et al., 1996) in a dose-dependent manner, i.e.,
greatest reduction in RNA binding seen with the largest
number of basic residues mutated.
In this study, using an in-frame deletion mutant of p7,
we showed that nucleocapsid is essential for efficient
assembly of HIV-1 and for the production of particles with
wild-type density. We assayed the role of the positively
charged N-terminal and central residues using muta-
tional analysis. We took advantage of the extensive bio-
chemical characterization of p7 which was carried out
using in vitro studies. We produced p7 mutations similar
to those which are defective for RNA binding in vitro
(Schmalzbauer et al., 1996) and expressed them in viral
constructs containing full-length HIV-1, to assay viral as-
sembly in transfected cells. In addition, a fusion protein
containing matrix and capsid of HIV-1 and a heterolo-
gous nonspecific RNA-binding domain from an unrelated
virus was constructed and assayed for its assembly
capability. The results of this study demonstrate that
nucleocapsid is required for efficient assembly and show
that the positively charged amino acids flanking the zinc
fingers are required for this function.
RESULTS
The C terminus of HIV-1 Gag is necessary for
efficient particle assembly
To map the functional requirements for assembly of
the C-terminal part of HIV-1 Gag, truncation mutants
were constructed with stop codons at sites which are
normally cleaved by the viral protease (Fig. 1A). Thus
stop codons were inserted by site-directed mutagenesis
at the end of the capsid domain and at the end of the p2
spacer peptide between p24 and p7. In addition, a trun-
cation was created within p7, with a stop codon directly
after the basic RKK motif between the zinc fingers. The
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mutants were assayed for viral assembly by transfection
into COS cells. Supernatants and cell lysates were har-
vested at 24, 48, and 72 h posttransfection and analyzed
by Western blotting with HIV-11 human serum for the
presence of viral proteins. Quantitation of viral assembly
was accomplished using NIH Image and comparing ra-
tios of released virus to intracellular viral protein for each
mutant for each time point. The virus and cell lysates
were collected every 24 h to determine whether defects
in virus release were the result of reduced virus particle
stability or due to reduced virus production at each time
point.
Western blots from a representative experiment are
shown in Figs. 2A–2C. Quantitation of these data are
shown in Figs. 2D–2F. In quantitation of virus release,
each truncation mutant was compared to the full-length
Gag construct (delta pol). The p24 truncation, lanes 2,
released some particles but at greatly reduced efficiency
compared to full-length Gag (lanes 5), about 2% of virus
release detected for delta pol at both 48 (Fig. 2E) and
72 h (Fig. 2F). Mutants which contained the N-terminal
part of p7, including the first zinc finger and the basic
charges (RKK) in the central globular domain, lanes 3,
were able to produce particles approximately 50 and 30%
as efficiently as delta pol at 48 (Fig. 2E) and 72 h (Fig. 2F),
respectively. These data indicate the essential role of the
C terminus of Gag in particle production.
Previous investigators (Hoshikawa et al., 1991; Jowett
et al., 1992) had observed that truncations of Gag at the
capsid-p2 boundary failed to release particles in bacu-
lovirus expression vectors in insect cells, while other
investigators (Royer et al., 1990, 1991) found some parti-
FIG. 1. (A) Diagram of truncation mutants of HIV-1 Gag. For details on construction of mutants, see Materials and Methods. Construct B2 expresses
whole HIV-1 Gag in the context of the whole HIV-1 genome. Delta pol contains a deletion of the entire pol gene. Construct p24 contains a stop codon
at the end of the capsid region of Gag, while p25 has a stop codon at the end of the spacer peptide p2 which occurs between capsid and
nucleocapsid. Delta p7 contains an in-frame deletion of nucleocapsid and contains all of p6. RKKs has a stop codon after the RKK residues (positions
32–34) between the zinc fingers of p7. B2LA consists of a fusion protein with a portion of the L-A virus pol gene fused downstream of the matrix and
capsid of HIV. (B) Diagram of point mutants in nucleocapsid. Mutant K2Q has lysines 11 and 14 changed to glutamines; mutant R3N has arginines
3, 7, and 10 changed to asparagines. Mutant E3 has the RKK residues at positions 32–34 of p7 changed to EEE. Mutants K2QE3 and R3NE3 combine
the N-terminal and central mutations.
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FIG. 2. Western blots of cell and virus lysates expressed in COS cells by transient transfection. Cell and virus lysates of truncation mutants, at 24 h
(A), 48 h (B), and 72 h (C) posttransfection. Lanes 1, mock; lanes 2, p24 truncation; lanes 3, RKKs; lanes 5, delta pol. The major protein bands in each
lane represent the truncated Gag proteins which all react with HIV-11 human serum. Lysates were prepared as described under Materials and
Methods. (D–F) Quantitation of the Western blots at 24, 48, and 72 h, respectively, as described under Materials and Methods.
cle release when Gag was truncated in the p2 region,
containing 11 amino acids of p2. Our data indicate that
particle release by the p24 truncation is indeed ineffi-
cient although some pelletable material was detected.
Another truncation mutant in this region, the p25 trunca-
tion contained a stop codon at the end of the p2 spacer
peptide, at the juncture between p2 and p7. This mutant
released virtually no pelletable material when expressed
in COS cells or in stable T-cell lines (data not shown). It
is not clear why the p25 truncation is even less compe-
tent to produce particles than p24. Previous studies us-
ing cleavage mutants at the p24–p2 junction have shown
that cleavage at this site is not necessary for assembly
(Pettit et al., 1994; Krausslich et al., 1995), indicating that
the presence of uncleaved p2 is not inhibitory to virus
assembly in the context of the whole Gag molecule.
However, a clear reproducible difference in assembly
capability was seen between the p24 and p25 constructs
in both cell types used. It is possible that the p24 parti-
cles represent some type of aggregation of Gag proteins
which is more readily formed with protein containing the
mature C terminus of p24 rather than the p25 precursor.
A nonspecific RNA-binding domain from another virus
stimulates assembly
In an effort to address the issue of nonspecific RNA
binding in viral assembly, a chimeric protein was con-
structed using the matrix and capsid domains of HIV-1
and the nonspecific RNA-binding domain of an unrelated
virus, the yeast L-A virus (Ribas et al., 1994a,b). The
RNA-binding regions of the pol protein of L-A virus had
been extensively characterized, allowing us to select a
region known to have nonspecific RNA-binding activity
and clone it into a fusion protein which was expressed in
the same COS cell system. Figures 2A–2C, lanes 4, show
the results of such a transfection experiment. The fusion
protein, B2LA, released virus particles about 13% as
efficiently as full-length Gag (delta pol) at 48 h (Fig. 2E)
and 4% at 72 h (Fig. 2F). The B2LA virus release at 48 h
(13%) is more efficient than the p24 truncation (2%) which
contains the same HIV-1 protein components (Fig. 2E).
However, the B2LA virus release (4%) at 72 h (Fig. 2F) is
scarcely different from that of the p24 truncation mutant
(2%). Although nonspecific RNA binding may be one
function of p7 in assembly, other functions such as cor-
rect protein folding or protein–protein interactions are
also likely to be required. The truncation mutant contain-
ing the first zinc finger (RKKs) assembles significantly
more than the B2LA chimera, suggesting that the assem-
bly functions of p7 cannot be replaced by an RNA-
binding function alone.
Point mutants in the positively charged regions
flanking the first zinc finger of p7 show a reduction in
viral assembly
Previous mutational analysis of p7 has shown that
the zinc fingers are largely dispensable for viral as-
sembly, although they are necessary for packaging of
the viral genome. However, the role of the flanking
basic residues in the process of virus assembly has
not been fully investigated. We constructed mutations
in these residues in the full-length viral DNA clone. We
chose mutations similar to those which had already
been studied biochemically for nonspecific RNA bind-
ing using purified p7 (Sheng and Erickson-Viitanen,
1994; Schmalzbauer et al., 1996), namely, mutation of
positively charged amino acids to negative charges in
the central linker region between the zinc fingers (ar-
ginine and lysine to glutamic acid) or changes of
lysines to glutamines and arginines to asparagines in
FIG. 2—Continued
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the N-terminal region of p7. These mutations are
shown in Fig. 1B. These constructs were used in COS
transfections; cell and virus lysates were examined for
virus assembly at 24, 48, and 72 h posttransfection as
described under Materials and Methods. The results
of a representative experiment are shown in Figs.
FIG. 3. Western blots of cell and virus lysates of p7 point mutants and p7-deletion mutant, expressed in COS cells, at 24 h (A), 48 h (B), and 72 h (C)
posttransfection. Lanes 1, mock; lanes 2, K2Q; lanes 3, R3N; lanes 4, E3; lanes 5, K2QE3; lanes 6, R3NE3; lanes 7, B2 (wild type.); lanes 8, delta p7. (D and
E) Quantitation of Western blots from the same experiment at 48 and 72 h posttransfection, respectively, as described under Materials and Methods.
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3A–3C. Quantitation of the 48 and 72-h time points is
shown in Figs. 3D and 3E. Since there was no detect-
able virus for the wild-type control or any of the mu-
tants (except the E3 mutant) at 24 h (Fig. 3A), no
quantitation could be done for this time point. Point
mutations of two lysines in the N terminus of p7 (K2Q,
lanes 2), caused a reduction in virus release to 60 and
24% of wild-type levels at 48 and 72 h, respectively,
while the changes of the three arginines (R3N, lanes 3)
reduced assembly to 60–70% at these time points. The
E3 mutation released virus at 18% of wild type at 48 h
and 40% at 72 h. In another study (Sheng et al., 1997)
the same mutant apparently showed no defect in virus
release. The reason for the discrepancy between
those results and the data described here is unclear.
Combined mutations in the N terminus and central
region had the greatest effect. The K2QE3 mutant
showed 6 and 30% virus release at 48 and 72 h, while
the R3NE3 mutant did not release detectable virus in
this experiment. In replicate experiments very low
levels of R3NE3 virus were seen, on the order of 3% of
wild type (data not shown). In summary, the mutants
with the greatest number of basic residue changes,
K2QE3 and R3NE3, show the greatest defect in virus
release. These results parallel the data published de-
scribing RNA binding by p7 in vitro, in which the
accumulation of numerous point mutations in basic
residues causes the greatest reduction in RNA binding
(Schmalzbauer et al., 1996). In our assembly study, we
find the greatest reduction in assembly in the mutants
which the greatest number of basic residues mutated.
An in-frame p7-deletion mutant shows drastic
reduction in assembly
To further define the C-terminal requirements for as-
sembly, an in-frame deletion of p7 was constructed by
engineering two novel restriction sites before and after
p7 and cutting and ligating. Results of virus release by
this mutant are shown in Figs. 3A–3C, lanes 8. This
mutant showed no detectable virus release in this ex-
periment. In experiments where delta p7 virus was de-
tected, the virus release was approximately 5- to 10-fold
reduced compared to wild type (data not shown). These
results are similar to those recently reported by other
investigators (Zhang and Barklis, 1997). The mutant also
shows less Gag cleavage in cell lysates than wild-type
virus (Figs. 3B and 3C, top). This could be due to several
causes, including a change in overall conformation of the
Gag polyprotein, a reduction in binding to RNA which
may contribute to reduced cleavage (Sheng and Erick-
son-Viitanen, 1994), or a reduced ability to interact with
the Pol proteins including viral protease. Apparently the
cleavage of the p25 capsid intermediate, which releases
mature p24, was affected in this mutant since no mature
p24 was detected. A band migrating at the size of p25,
not seen in the mock cell lysate, was reproducibly seen
in Western blots of the cell lysate from delta p7.
Transfection experiments were also carried out using
the p7-deletion mutant in the presence of the HIV-1
protease inhibitor SC5121 (Bryant et al., 1995) to deter-
mine whether protease cleavage has any effect on virus
release in this mutant. Under conditions where cleavage
FIG. 3—Continued
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was inhibited in wild-type and mutant transfected cells,
the mutant still showed a 5- to 10-fold reduction in virus
release (data not shown).
Reduction in virus release compared to soluble Gag
release measured by p24 ELISA
A standard p24 ELISA assay was carried out to mea-
sure total Gag protein released in the supernatant of
transfected COS cells, using samples from the same
experiment shown in Fig. 3. Results of the p24 assay are
shown in Fig. 4. At 24 h, total Gag protein release by the
mutant viruses is barely above mock levels (Fig. 4A). At
48 and 72 h, there is a significant reduction in Gag
protein release by the mutants compared to wild-type
virus, indicating that at least some portion of the defect in
virus particle production cannot be explained by a lack of
particle stability. If virus particles were produced at lev-
els equivalent to wild type but failed to remain stable in
the supernatant, the total Gag protein levels would be
similar for mutant and for wild-type virus. At 48 h, the
levels of Gag protein (Fig. 4B) parallel closely the levels
of virus release (Fig. 3D), with the greatest defects in
virus release seen in the mutants E3, K2QE3, R3NE3, and
delta p7. There is some detectable Gag released by the
R3NE3 and delta p7 mutants, as measured by p24 assay
(Fig. 4B), while Western blots showed no detectable virus
(Fig. 3D). It is possible that a small amount of mutant
virus is produced and is highly unstable. At 72 h there is
a more noticeable difference between p24 assay results
and Western blot for the R3NE3 and delta p7 mutants.
Since more soluble Gag protein is apparently released
than virus which is pelletable through sucrose, it ap-
pears likely that particle stability may be one defect
associated with these p7 mutations.
Production of particles with the correct density
requires the C terminus of Gag
One characteristic of particles assembled without C-
terminal Gag domains (in HIV-1) or without nucleocapsid
(in other retroviruses) is a density which is lighter than
that of wild-type virions [1.16–1.17 g/ml, typically (Jowett et
al., 1992; Bennett et al., 1993)]. To assay virus density,
concentrated virus was overlaid on linear 60–12% su-
crose gradients and fractions collected and analyzed by
Western blotting assay. To obtain enough concentrated
virus to carry out these experiments, stable T-cell lines
were constructed as described under Materials and
Methods. In each case, wild-type and delta pol-express-
ing stable T-cell lines were used for comparison with
mutant T-cell lines. Supernatants from stable T-cell lines
expressing the p24 truncation or the wild-type virus were
collected and concentrated by pelleting over 20% su-
crose before loading onto the sucrose gradients. As
shown in Fig. 5A, the density of particles produced by the
p24 truncation was approximately 1.09–1.15 g/ml, com-
pared to wild-type density of 1.18–1.19 g/ml in a gradient
prepared in the same experiment. The Gag-only particles
produced by the delta pol construct also show wild-type
density, both in this experiment and in subsequent ex-
periments where wild-type and delta pol controls were
run side by side (data not shown).
The delta p7 particles, shown in Fig. 5B, also prepared
FIG. 4. p24 ELISA results for transfection of p7 point mutants and deletion mutant at 24 h (A), 48 h (B), and 72 h (C) posttransfection. Samples were
collected from COS supernatants for p24 assay at the indicated time points, and the remainder of the supernatants analyzed by Western blot as
described in Fig. 3. p24 release was adjusted for intracellular Gag protein levels as measured and quantitated by Western blot of cell lysates, as
described under Materials and Methods.
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from supernatants from stable T-cell lines, had a density
lighter than wild-type density, 1.10–1.14 g/ml compared to
1.15–1.18 g/ml for delta pol, which is consistent with
results that had been reported for other viruses (Bennett
et al., 1993). Mutant construct RKKs which contained the
N-terminal part of p7, including the first zinc finger and
the basic charges (RKK) in the central globular domain,
produced particles with a wild-type density (data not
shown). When the B2LA particles were assayed (Fig. 5C),
their density overlapped the density of delta pol particles,
namely 1.14–1.18 g/ml compared to 1.16–1.17 for delta pol
in the same experiment. It is not clear what structural
differences in virions lead to differences in density. Pro-
tein–protein interactions or protein packing may vary and
protein–nucleic acid interactions may be involved. An-
other factor that is known to affect particle density is the
presence of the lipid membrane which surrounds the
viral core; however, it is unlikely that there are differ-
ences in membrane association of these mutants com-
pared to the wild-type virus because the main membrane
targeting signals have been left intact. Furthermore, the
lack of lipid membranes results in particles which are
denser than wild type not lighter (Campbell and Vogt,
1995, 1997; Lingappa et al., 1997), making it unlikely that
changes in membrane content can explain the density of
these mutants. Further biochemical and electron micros-
copy analysis of mutant virions is necessary to deter-
mine their structural characteristics.
Intracellular cleavage of mutant Gag proteins
containing point mutations in nucleocapsid
Results in Fig. 3 suggested that more CA-P2 (p25) was
accumulated in cells transfected with nucleocapsid point
mutants. To evaluate the efficiency of p7 cleavage in
cells transfected with nucleocapsid point mutants, cell
lysates were analyzed by Western blots using an anti-p7
monoclonal antibody. Some polyclonal antisera which
reacted strongly to wild-type p7 failed to react to mutant
p7 in cell lysates (data not shown), therefore the weaker
monoclonal anti-p7 antiserum was used since it reacted
well with all of the mutants. The presence of cleaved p7
protein was detected in all of the point mutants (Fig. 6A)
but not, as expected, in the p7-deletion mutant construct.
Because the p7 antibody did not detect the p15 interme-
diate which contains both p6 and p7, we could not de-
termine directly if there was a defect in cleavage of the
p15 intermediate for these mutants. Other investigators
(Sheng and Erickson-Viitanen, 1994; Sheng et al., 1997)
have shown that the basic residues in between the zinc
fingers of p7 are required for efficient p15 cleavage in
vitro and in transfected cells. These same investigators
found that cleavage at other sites appeared normal, with
the exception of an excess of p25 (capsid plus p2)
intermediate. Our data indicate that p7 is cleaved from
the Gag polyprotein as efficiently or more efficiently than
wild type for several of the point mutants (Fig. 6B, K2Q,
R3N, and E3). The two mutants with most basic residues
altered, K2QE3 and R3NE3, seem to have slightly less
cleaved p7 relative to full-length Gag. However, it is not
clear if this is significantly different from the wild-type
cleavage. These mutants, along with the other point
mutants in p7, also showed greater amounts of certain
Gag intermediates such as p41 and p25, compared to
wild type, in cell lysates (Figs. 3B and 3C, and data not
shown). It is not clear in the case of K2QE3 and R3NE3
if there is a defect in Gag processing at the p7-p6
cleavage sites or at other steps in Gag processing since,
as mentioned above, the p15 intermediate could not be
detected using the p7 monoclonal antibody. Also, due to
the reduction in virus particles produced by the mutants,
it was not possible to accurately measure p7 cleavage in
the released virions.
DISCUSSION
Previous studies in HIV-1 using truncation mutants
(Royer et al., 1990, 1991; Hoshikawa et al., 1991; Jowett et
al., 1992; Kaye and Lever, 1996) have demonstrated that
the C terminus of Gag, including p7 and p6, is necessary
for efficient viral assembly, using a variety of eukaryotic
expression systems, including baculovirus, stable T-cell
lines, and transiently transfected COS cells. A recent
study involving truncations of HIV-1 Gag and deletions of
nucleocapsid (Zhang and Barklis, 1997) showed that nu-
cleocapsid is required for efficient virus assembly. These
investigators found that p7-deletion mutants failed to
encapsidate HIV-1 RNA, a finding consistent with previ-
ous studies implicating p7 in specific RNA recognition. In
addition, deletion mutants of RSV have shown that the
nucleocapsid domain is essential for assembly in these
viruses (Weldon et al., 1990; Dupraz and Spahr, 1992;
Bennett et al., 1993). Several studies have shown that
nucleocapsids can be switched in chimeric Gag proteins
and can assemble and package the RNA appropriate to
the nucleocapsid domain (Dupraz and Spahr, 1992;
Berkowitz et al., 1995; Zhang and Barklis, 1995). A recent
study investigated the role of protein–protein interactions
in viral assembly by fusing various oligomerization do-
mains from heterologous proteins to the C terminus of
the capsid protein (Zhang et al., 1998). This study
showed that oligomerization domains were effective in
restoring assembly capability to truncated Gag mole-
cules.
In this study an in-frame deletion mutant of HIV-1
nucleocapsid demonstrates that the p6 domain of HIV-1
is unable to complement the assembly defect seen when
p7 is deleted. In addition, we have demonstrated that the
p7 domain of HIV-1 is necessary for formation of parti-
cles with wild-type density. Similar observations have
been made by other investigators (Jowett et al., 1992;
Bennett et al., 1993; Zhang and Barklis 1997) studying
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deletion mutants of RSV and deletions and truncations of
HIV-1. It is clear from the present study that p6 is not
sufficient to restore proper density to particles that lack
p7. A chimeric protein which contains a heterologous
RNA-binding domain is able to stimulate formation of
particles with correct retroviral density, implying that
RNA binding may be one of the functions required for
retroviral assembly.
The nucleocapsid domains of retroviruses have been
extensively characterized in terms of their role in pack-
aging of the viral genome. The relationship between
packaging and viral assembly is not straightforward,
however, since many mutants in nucleocapsid of HIV-1
and other retroviruses fail to package the viral genome
and yet assemble efficiently. The process of RNA pack-
aging in retroviruses has been extensively studied, not
only to gain a greater understanding of the retrovirus life
cycle but also for the exploitation of retroviral vectors as
vehicles for delivery of heterologous genes in gene ther-
apy. The presence of cis-sequences in the RNA genomes
has been meticulously investigated (Linial et al., 1978;
Lever et al., 1989; Aldovini and Young, 1990; Aronoff et al.,
1993; Berkowitz et al., 1993; Berkowitz and Goff, 1994;
Luban and Goff, 1994) as well as the requirement for
zinc-finger motifs in the nucleocapsid domains of all
retroviruses studied so far (Gorelick et al., 1988; Meric
and Spahr, 1988; Meric and Goff, 1989; Dupraz et al.
1990; Dupraz and Spahr, 1992; Dannull et al., 1994) with
FIG. 5. Sucrose density gradients. Samples were prepared and run on linear sucrose gradients as described under Materials and Methods.
Fractions were collected from each gradient, TCA precipitated, and run on gels for Western blotting. Gradients were prepared and run simultaneously
for mutant and controls in each experiment. In the far right lane of each gel is a control sample of cell lysate from wild-type (B2) transfected cells.
Peak fractions for each virus have densities as follows: (A), p24 truncation, 1.09–1.15; delta pol, 1.18–1.19; and B2 wild-type virus, 1.17–1.19; (B), B2LA
fusion protein, 1.14–1.17; delta pol, 1.16–1.17; (C), delta p7, 1.10–1.14; delta pol, 1.15–1.18.
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the exception of foamy viruses which do not contain zinc
fingers (Yu et al., 1996). However it has been well docu-
mented that mutants in either the cis-packaging se-
quences or trans-factors, namely the nucleocapsid zinc
fingers, are generally able to assemble quite efficiently,
even when they package less than 10% of the viral RNA
compared to wild-type virus. Generally speaking, the
presence of the viral genome is not required for the
assembly process; mutant viruses that lack genomic
RNA have been shown to have correct viral density, and
protein composition, although electron microscopy re-
vealed abnormal core structure for some packaging mu-
tants (Aldovini and Young, 1990; Clavel and Orenstein,
1990). However, several investigators have pointed out
the presence of cellular RNAs in these mutant viruses,
which are packaged with varying degrees of efficiency in
viruses mutated in nucleocapsid which lack the specific
recognition of their own genome (Linial and Hayward,
1978; Meric and Goff, 1989). In contrast to the specific
recognition of genomic RNA which is mediated in part by
the zinc fingers, probably in the context of the Gag
polyprotein before cleavage, the nonspecific RNA-bind-
ing ability of the nucleocapsids has been shown to be
mediated by patches of basic amino acids flanking the
zinc fingers (De Rocquigny et al., 1992, 1993; Berkowitz
and Goff, 1994; Housset et al., 1993; Muller et al., 1994;
Schmalzbauer et al., 1996). Hence the mutation or even
deletion of the zinc fingers would not be expected to
abolish all protein–RNA interactions by the polyprotein.
The recent NMR structure of p7 bound to an RNA stem
loop from the HIV-1 packaging sequence confirms that
the basic residues in the N terminus are involved in
protein–RNA interactions in a nonspecific fashion
(DeGuzman et al., 1998). In vitro studies of various mu-
tants in the basic charge regions of p7 have shown that
these residues are indeed important in nonspecific RNA
binding (Schlesinger et al., 1994; Sheng and Erickson-
Viitanen, 1994). In this study we produced identical or
similiar mutations in the context of the whole virus and
assayed the ability of the basic domain mutants to as-
semble in transfected cells. The results of these exper-
FIG. 6. Western blot of cell lysates of p7 mutants stained with
monoclonal antibody to p7. (A) Western blot of cell lysates at 72 h was
prepared as described under Materials and Methods and stained with
a mouse monoclonal antibody reactive with p7 and with full-length Gag.
(B) Quantitation of p7 cleavage, expressed as a ratio of p7 to p55 and
2 Gag cleavage intermediates, using NIH Image as described under
Materials and Methods.
FIG. 5—Continued
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iments show that the basic domains in p7 are important
for viral assembly. Two previous investigations, however,
showed that mutations of basic residues in the N-termi-
nal region or in the linker region between the fingers did
not significantly affect viral assembly (Ottman et al., 1995;
Poon et al., 1996). A crucial difference between these
mutagenesis studies and the present one is that the
basic amino acids were changed to neutral ones (Ott-
man et al., 1995) instead of negatively charged residues
(this study) at positions 39–41 and residues were
changed to the more conservative alanine substitutions
(Poon et al., 1996) in the N terminus rather than glu-
tamines and asparagines (this study). Also, in this study
mutants were constructed with five- and six-point muta-
tions in the N terminus and central domain, a larger total
number of point mutations than had been previously
tested in this region.
In vitro assembly studies using purified retroviral Gag
proteins have shown a clear requirement for RNA in the
assembly of either tubular or spherical structures (Camp-
bell and Vogt, 1995, 1997). The RNA does not have to be
virus-specific. These in vitro studies imply that nonspe-
cific RNA binding by Gag polyproteins may be an essen-
tial component of the assembly process. Other in vitro
systems which have been shown to assemble virus-like
particles are reticulocyte lysates (Spearman and Ratner,
1996) and cell-free extracts which were derived from
wheat germ extracts (Lingappa et al., 1997). Both of these
expression systems contained RNA which was used for
in vitro translation, although the role of RNA in the as-
sembly reaction was not specifically addressed. Among
RNA viruses in general there exist various strategies for
combining the process of virus assembly and RNA pack-
aging (reviewed by Schlesinger et al., 1994). In several
RNA viruses, the RNA–protein interactions between the
core protein and the genome form an essential part of
both the assembly process and the stabilization of the
mature virus particle (reviewed Harrison, 1995). While
mutants of some viruses are able to assemble empty
capsids which contain no RNA, other viruses are only
found as RNA-containing cores. Three-dimensional
structures of several viruses reveal the specific interac-
tion between RNA and several molecules of core protein
and implicate these interactions in stabilization of the
viral particle (Fisher and Johnson, 1993). The evolution-
ary advantages of these properties seem obvious: the
virus will always capture the relevant RNA if specific
RNA–protein interactions are required for assembly; the
coating of viral RNA with core proteins may assist in
shifting activity from active translation to packaging of
viral genomes (Sonstegard and Hackett, 1996); and
RNA–protein interactions that stabilize the particle rela-
tive to empty capsids would ensure that fully infectious
viral particles have a selective advantage over defective
particles lacking viral genome.
Although the ability of NC to bind nucleic acids is
clearly demonstrated for both the purified p7 protein and
in the context of p55 Gag, other functions of NC in the
assembly process cannot be ruled out and in fact are
likely to play a significant role. The conformation of the
polyprotein is likely to be affected by alterations or de-
letions in p7. Also, other investigators (Bennett et al.,
1993; Franke et al., 1994; Spearman et al., 1994) have
proposed that NC domains can mediate important pro-
tein–protein interactions in the Gag polyprotein, and
these interactions could be a significant factor in efficient
assembly. Clearly the three types of functions—nucleic
acid binding, protein conformation, and protein–protein
interaction—are not mutually exclusive, and all three are
likely to be involved in nucleocapsid’s role in the assem-
bly process.
An intriguing possibility for regulation of assembly by
nucleocapsid domains of retroviruses is the link between
translation and packaging of the RNA genome. As has
been recently studied in RSV (Sonstegard and Hackett,
1996), Gag can serve as a translational repressor and
thus regulate the use of viral RNA first for translation and
then for packaging into viral particles. This observation is
consistent with a model of assembly that begins with
Gag polyproteins binding to viral RNA during the first
stages of multimerization. As some in vitro data have
shown, cleavage of the viral polyprotein can be en-
hanced by RNA binding (Sheng and Erickson-Viitanen,
1994; Sheng et al., 1997). Correct regulation of protease
cleavage is necessary to ensure that all Gag compo-
nents get incorporated in equimolar amounts into virions.
It is possible that Gag polyproteins interacting with RNA
through the nucleocapsid domain first multimerize and
then become accessible to cleavage at an appropriately
late stage in viral assembly. The fact that the p7-deletion
mutant and several basic charge mutants in p7 are
cleaved less than the wild-type Gag could support this
argument. Alternatively, it also could be argued that the
mutations cause the polyprotein to fold differently and
hence be less accessible to the viral protease, with or
without the presence of RNA or that membrane targeting
is affected by these mutations in p7, with a resulting
defect in protease processing. Studies of RNA binding
and cleavage of the polyprotein in vitro would have to be




Site-directed mutagenesis was accomplished using
the Mutagene kit (BioRad), using single-stranded DNA
templates created from two plasmids: pGEM7ZSA, which
contains an SstI to ApaI fragment of HXB2 (nucleotides
228–1556), and pGEM5ZAE, which contains the ApaI to
EcoRV fragment (nucleotides 1556–2525). Truncation p24
was created in pGEM7ZSA by substituting a stop codon
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(TAA) for the alanine at position 364 of Gag; truncation
p25 was made from the same plasmid by substituting a
stop codon (TAA) for the methionine at position 378 of
Gag. The mutants were then cloned into a subcloning
vector, pGEM3ZPS, which contains the 965–5332 frag-
ment of HXB2, using the PstI and ApaI sites. The final
cloning step involved cloning the SpeI-SalI fragments
from each mutant pGEM3ZPS into an infectious viral
clone, either HXB2neo (Lee et al., 1997) or HXB2. Trun-
cation RKKs was created by PCR mutagenesis using
HXB2 as a template, with the 59 oligonucleotide span-
ning the beginning of Gag and the 39 oligo spanning
nucleotides 1590–1556 of HXB2. The 39 oligo contained a
stop codon (TAG) substituted for amino acid 35 (cysteine)
at nucleotide 1572, and in addition a novel SalI site at
nucleotides 1574–1579. An SpeI-SalI fragment was cut
out of this PCR product, using the SpeI site at nucleotide
1053 and the novel SalI site at the 39 end, and the
fragment was cloned into HXB2 using the SalI site after
the pol gene (nucleotide 5332) and the unique SpeI site
at nucleotide 1053. The E3 mutant was also constructed
using PCR mutagenesis but with a 59 oligo spanning
nucleotides 1590–1556, which contained the RKK-to-EEE
substitution at amino acids 23–24 of p7, and a 39 oligo
which spanned the 39 end of the gag gene. The RKK-to-
EEE mutation generates a novel Bsu36 site which was
used to screen the subsequent cloning steps. This mu-
tation was cloned into pGEM3ZPS using a two-step di-
gestion and ligation procedure. The 3.0-kb PCR fragment
was digested first with BglII and ligated to a BglII, ApaI
digested 7-kb plasmid, pGEM3ZPS. The resulting 10-kb
linear DNA was digested with ApaI to remove the 59 end
of the PCR product and religated. The result of this
ligation was an ApaI-to-BglII fragment from the PCR
product replacing the ApaI-BglII segment of pGEM3ZPS.
The SpeI-SalI fragment of the mutant pGEM3ZPS was
cloned into HXB2. The point mutations in nucleocapsid,
K2Q and R3N, were created by site-directed mutagene-
sis using the ssDNA template pGEM5ZAE, with lysine to
glutamine substitutions at amino acids 11 and 14 (K2Q)
and arginine-to-asparagine substitutions at amino acids
3, 7, and 10 (R3N). These mutations were subcloned into
pGEM3ZPS using the ApaI and EcoRV sites, and then the
SpeI-SalI fragment of the resulting mutant pGEM3ZPS
was cloned into HXB2Neo. Each of these mutants was
combined with the RKK-to-EEE mutation by subcloning
an ApaI-to EcoRV fragment of E3 into the pGEM3ZPS
plasmid harboring the K2Q or R3N mutation upstream of
the ApaI site. The resulting pGEM3ZPS mutant plasmid
then contained either five (K2QE3) or six (R3NE3) point
mutations and was cloned into the HXB2Neo, using SpeI-
SalI. The p7-deletion mutant was created by engineering
two novel NotI sites in two different plasmids. In one
plasmid, pGEM3ZSA, a novel NotI site was created at
nucleotides 1426–1434, at the end of the capsid region of
Gag. In the other plasmid, pGEM5ZAE, a NotI site was
created at nucleotides 1621–1629. The deletion of p7 was
accomplished by cutting pGEM5ZAE with ApaI and NotI,
isolating the plasmid vector, and inserting the ApaI to
NotI insert from pGEM7ZSA. The resulting plasmid con-
tained a deletion of p7 and was then cloned into
pGEM3ZPS and the SpeI-SalI fragment from that sub-
clone inserted into HXB2neo. The B2LA fusion protein
was created by using PCR to amplify a region of the pol
gene (nucleotides 2914–3300) of the yeast L-A virus,
using a template kindly provided by Dr. R. Wickner. The
PCR oligos contained restriction sites, NotI at the 59 end,
and EcoRI at the 39 end, and a stop codon engineered at
nucleotide 3202 of the L-A pol gene. The PCR fragment
was digested with NotI and EcoRI and cloned into
pGEM3ZPS, which contained a NotI site at the end of the
capsid region (described above in the mutagenesis of
delta p7) and EcoRI at position 5289. This resulted in the
fusion of the L-A pol fragment to the capsid of HIV-1, and
the deletion of nucleocapsid, p6 and pol of HIV-1. The
mutant was then cloned into HXB2Neo using SpeI and
SalI. The delta pol construct was created using PCR of
the whole gag gene, creating an EcoRI site at nucleotide
1839 with the 39 oligo and using a 59 oligo spanning
nucleotides 320–349. The Gag fragment was digested
with SpeI and EcoRI and cloned into an HXB2Neo back-
bone which has been digested with the same enzymes,
thus deleting the pol gene (nucleotides 1839–5289 de-
leted). Mutations in these plasmids were confirmed by
restriction enzyme analysis or dideoxy sequencing
(USB).
Cell culture and transfections
COS-7 cells were maintained in DMEM plus 10% fetal
calf serum and antibiotics (Gibco, Gaithersburg, MD). H9
and SupT1 T-cell lines were grown in RPMI 1640 plus
10% fetal calf serum and antibiotics. Protease inhibitor
SC52151 (Bryant et al., 1995) was generously supplied by
Dr. C. Flexner. COS cell transfections were performed
using the DEAE dextran method. Briefly, cells were
trypsinized, washed once, and resuspended in TD buffer
(25 mM Tris-HCl, pH 7.4; 140 mM NaCl; 5 mM KCl; 0.7
mM K2HPO4) containing 500 mg/ml DEAE-dextran (Sig-
ma, St. Louis, MO) and the relevant plasmid DNA at a
concentration of 2 mg/ml for each T75 flask of cells,
except mock transfections which contained no DNA.
Cells were incubated for 45 min at 37°C, washed once
with complete medium (DMEM with 10% fetal calf serum)
and plated in T75 flasks. At 24, 48, and 72 h posttrans-
fection, supernatants were collected and cells were
scraped from the flask, washed once, and lysed in a
small volume of RIPA buffer (0.15 M NaCl; 0.05 M Tris, pH
7.2; 1% Triton X-100; 1% Na deoxycholate; 0.1% SDS). Cell
lysates were cleared by centrifugation in Eppendorf
tubes for 30 min in a table-top microcentrifuge; the su-
pernatant from this spin was removed to a fresh tube and
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mixed with sample loading buffer for SDS–PAGE. The
supernatants from the COS transfections were cleared of
cell debris by centrifugation for 10 min at 3000 rpm in a
table-top centrifuge, then filtered through 0.2-mm filters
(Millipore, Bedford, MA) and centrifuged at 20,000 rpm in
a Sorvall ultracentrifuge, AH-629 rotor, over a 20% su-
crose cushion. Viral pellets were resuspended in RIPA
buffer at approximately 1/1000 of the starting supernatant
volume and the samples mixed with loading buffer for
SDS–PAGE. Stable T-cell lines were generated by using
lipofection (Felgner et al., 1987) with liposomes prepared
as described (Rose et al., 1991) using dioleoyl-L-a-phos-
phatidylethanolamine and dimethyldioctadecylammo-
nium bromide (Sigma). Liposomes and the relevant plas-
mids containing the neo resistance marker were mixed
with T cells and incubated for 16–24 h at 37°C. The cells
were washed, placed in complete medium (RPMI plus
fetal calf serum), and 24 h later medium was replaced
with complete medium containing G418 (Gibco) at a
concentration of 1.2 mg/ml. The cells were maintained in
this selection medium for several weeks before growth
of neo-resistant cells was observed. The stable cell lines
were then assayed for viral gene expression; superna-
tants and cell lysates were prepared for SDS–PAGE as
described above.
Sucrose density gradients
Sucrose gradients were prepared by hand, layering
either 2.2 or 2.4 ml of 12 sucrose stock solutions pre-
pared in TSE (10 mM Tris, pH 7.5; 100 mM NaCl; 1 mM
EDTA) in 36-ml ultracentrifuge tubes, using 60 to 16%
sucrose (stock solutions differing in sucrose concentra-
tion by steps of 4%). Virus which had been collected from
T cell supernatants was prepared as described above for
SDS–PAGE except that the virus was resuspended in
PBS (140 mM NaCl, 3 mM KCl, 8 mM Na2HPO4, 1.5 mM
KH2PO4) after ultracentrifugation instead of RIPA. The
volume of virus samples loaded on gradients was ad-
justed so that each gradient had an equivalent volume of
PBS added prior to equilibrium centrifugation. Gradients
were centrifuged for 12 h at 20,000 rpm in a Sorvall
AH-629 rotor. Fractions were collected by puncturing the
bottom of the tube and collecting 14 or 16 fractions of
approximately 1.8 ml each. Because gradients prepared
in different experiments had different volumes of sucrose
or different numbers of fractions, each mutant was al-
ways compared to a control (either wild-type virus or
delta pol) which was run on an identical gradient in the
same experiment. Fractions were assayed for density by
weighing 100-ml samples on an OHaus analytical bal-
ance. Protein was precipitated from the fractions by TCA
precipitation and used for Western blot analysis. TCA
precipitation was carried out by mixing a 500-ml sample
with 26 ml 10% Triton X-100, adding 56 ml of 100% TCA,
incubating on ice for 15 min, and spinning down in a
table-top microfuge for 15 min. The precipitates were
washed with 1 ml of acetone, dried, and resuspended in
SDS–PAGE sample buffer for gel loading.
Western blotting
SDS–PAGE was carried out using standard methods.
Proteins were transferred to nitrocellulose (Schleicher
and Schuell) by washing the gel and nitrocellulose in
transfer buffer (50 mM NaCl, 1.8 mM EDTA, 10 mM Tris,
pH 7.0) and making a sandwich of nitrocellulose sheets
with the gel in the middle, wrapping with plastic wrap,
and incubating overnight between two glass plates with
a 2 kg weight on top at 4°C. The blots were stained using
HIV-11 human serum in a PBS solution with 3% nonfat
dried milk. Secondary antibodies were alkaline phos-
phatase-conjugated anti-human or anti-mouse (Jackson
Immunoresearch, Inc., West Grove, PA) and staining was
with BCIP and NBT solutions prepared from chemicals
obtained from Sigma. Quantitation of Western blots of
intracellular and viral proteins was carried out with the
NIH Image Program, version 1.52. All Western blots were
determined to be in the linear range by making dilution
curves of cell lysates and virus lysates and quantitating
the results. All transfections were performed in parallel
and a complete set of cell lysates and virus lysates was
run on the same Western blot for quantitation. Western
blots were scanned using an Eagle Eye, and digital
images were analyzed using NIH Image. The major pro-
tein bands for each mutant were scanned and the ratio of
virus to cell protein expressed using numerical output
(pixels).
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